• Ridaforolimus (Deforolimus): Applied mTOR Inhibition in Canc

  2026-04-22

  Ridaforolimus (Deforolimus) delivers robust, selective mTOR pathway inhibition, empowering reproducible workflows in cancer biology and angiogenesis studies. This guide unpacks protocol best practices, troubleshooting, and how recent machine learning advances in senolytics inform applied experimental design.

• Adipose-Neural Axis and Cardiac Arrhythmias: New Mechanistic

  2026-04-22

  Fan et al. (2024) provide compelling evidence that the adipose-neural axis, particularly the interplay between leptin and neuropeptide Y signaling, contributes to arrhythmogenesis in cardiac tissue. Their stem cell-based coculture model elucidates new intervention targets, with implications for translational research in arrhythmia and neurocardiac modulation.

• Lanabecestat (AZD3293): Precision BACE1 Inhibition in Alzhei

  2026-04-21

  Lanabecestat (AZD3293) empowers researchers to selectively inhibit BACE1 with nanomolar potency, enabling precise modulation of amyloid-beta production in preclinical Alzheimer’s models. Recent evidence supports moderate, synaptic-sparing dosing strategies, making this APExBIO compound a gold standard for translational workflows targeting the amyloidogenic pathway.

• Host-Directed GSK3 Inhibition Controls Mycobacterium tubercu

  2026-04-21

  This study identifies glycogen synthase kinase 3 (GSK3) inhibition as a host-directed strategy to limit Mycobacterium tuberculosis growth within macrophages. The findings highlight a potential alternative to conventional antibiotics, supporting further research into host-targeted therapies for persistent and drug-resistant tuberculosis.

• Practical Guide: Pexidartinib (PLX3397) for CSF1R Pathway St

  2026-04-20

  Pexidartinib (PLX3397) is a selective ATP-competitive CSF1R inhibitor, designed to modulate macrophage dynamics and inhibit CSF1R-mediated signaling in tumor microenvironment research. It is best suited for cell-based and preclinical workflows requiring precise CSF1R pathway inhibition and apoptosis induction. Researchers should avoid its use in diagnostic or clinical settings due to its research-only designation.

• Fingolimod (FTY720): Applied Workflows for Immunomodulation

  2026-04-20

  Fingolimod (FTY720) stands at the intersection of immunomodulation and neuroprotection, delivering reproducible control over lymphocyte trafficking and BDNF upregulation. This article details stepwise protocols, advanced use-cases, and real-world troubleshooting for maximizing the translational impact of APExBIO’s high-purity Fingolimod in both autoimmune and solid tumor models.

• Sorafenib (A3009): Reliable Multikinase Inhibition for Cance

  2026-04-19

  This article provides laboratory-validated guidance for using Sorafenib (SKU A3009) as a multikinase inhibitor in cancer biology and host-pathogen studies. Drawing on quantitative benchmarks and real-world scenarios, it demonstrates how APExBIO’s Sorafenib delivers reproducible, data-backed results in cell viability, proliferation, and kinase pathway assays, supporting best practices for experimental reliability.

• OTUD3-Mediated SLC7A11 Stabilization Drives Sunitinib Resist

  2026-04-18

  This study uncovers how the deubiquitinase OTUD3 stabilizes SLC7A11, suppressing ferroptosis and promoting resistance to sunitinib therapy in clear cell renal cell carcinoma (ccRCC). The mechanistic insight into OTUD3-SLC7A11-GSH signaling suggests new targets for overcoming drug resistance and optimizing therapeutic strategies.

• Reserpine (SKU N1867): Workflow Parameters for Lab Use

  2026-04-17

  Reserpine is a high-purity, research-grade alkaloid designed for scientific studies involving neurotransmitter depletion, antihypertensive mechanism investigations, and neuropharmacology workflows. Its defined solubility and stability parameters support reproducibility, but it should not be used for diagnostic or clinical applications.

• BML-277: A Potent Chk2 Inhibitor for DNA Damage Response Wor

  2026-04-16

  BML-277 stands out as a highly selective Chk2 inhibitor, transforming DNA damage response and radioprotection studies with nanomolar potency. Discover how this compound streamlines T-cell survival assays, enables mechanistic exploration of the Chk2–cGAS–TRIM41 axis, and optimizes experimental reproducibility for cancer and genome stability research.

• Triacetin in Translational Research: Mechanisms & Strategies

  2026-04-15

  This thought-leadership article explores Triacetin’s (glyceryl triacetate) unique mechanistic pathways, including HDAC-8 inhibition and AMPK activation, and provides actionable guidance for translational researchers targeting metabolic disorders, adipogenesis, and glioblastoma. By integrating recent in vitro and in vivo evidence with strategic protocol parameters, and referencing both the landmark Bauhinia divaricata antiadipogenic study and advanced workflow assets, the article positions APExBIO’s Triacetin (BA1710) as a next-generation lipid-related biochemical reagent essential for bridging epigenetic modulation and metabolic reprogramming in advanced life science workflows.

• Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod

  2026-04-14

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, closely mirroring the tumor microenvironment. The approach demonstrates enhanced physiological relevance for studying drug responses and resistance, supporting more precise preclinical evaluation and personalized therapy design.

• Silybin A: Mechanistic Leverage for Translational Liver Rese

  2026-04-13

  This thought-leadership article dissects the mechanistic roles of Silybin A, a principal component of Silymarin, in the context of liver disease, metabolic modulation, and inflammation. Bridging bench-to-bedside workflows, it offers translational researchers actionable guidance on integrating Silybin A (APExBIO, SKU N1711) into innovative protocols—contrasting gene-editing approaches—while providing evidence-led insights, protocol parameters, and a forward-looking outlook on hepatoprotective strategies.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Technical Guide

  2026-04-13

  The FITC Goat Anti-Mouse IgG (H+L) Antibody provides reliable, sensitive detection of mouse IgG primary antibodies in immunofluorescence and flow cytometry workflows. It is best suited for applications requiring high specificity and low background, but should not be used in protocols demanding cross-species reactivity or in non-fluorescent detection systems. Researchers should adhere closely to product storage and handling recommendations to maintain signal fidelity.

• Targeted Inhibition of SPP1 in Tumor Macrophages Reduces Tum

  2026-04-12

  This study introduces a phenotypic screening approach to identify small molecules that suppress SPP1 expression in tumor-associated macrophages (TAMs), culminating in a TAM-targeted nanoformulation that demonstrated significant tumor remission in preclinical models. The findings provide foundational evidence for developing macrophage-directed therapies to modulate the tumor microenvironment and improve cancer outcomes.

15287 records 1/1020 page Next 12345 下5页 Last page